Evaluation of Residual Symptoms and Anxiety Among Patients on Therapy for Benign Prostatic Hyperplasia at a Nigerian Tertiary Healthcare Facility

The study evaluated residual symptoms and anxiety among 412 outpatients undergoing therapy for benign prostatic hyperplasia (BPH) at a Nigerian healthcare facility. Using the Memorial anxiety scale for prostate cancer (MAX-PC) and the expanded prostate cancer index composite for clinical practice (EPIC-CP), it was found that 44.3% of patients experienced high anxiety levels, primarily due to fears of recurrence (91.3%), BPH progression (23.3%), and prostate-specific antigen tests (9.3%). Common residual symptoms included sexual dysfunction (96.1%), urinary incontinence (37.6%), and urinary obstruction (34.5%). There was a significant association between residual symptoms and demographic factors (p<0.001), highlighting the need for routine anxiety assessment and treatment to improve patients' quality of life.